Announcement

The world’s first pill to treat COVID-19 set for approval

Merck and Merck and Ridgeback Biotherapeutics today announced that the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months. The submission is based on positive results

White House confirms plans to nominate Africa CDC head to lead PEPFAR

The White House has confirmed that President Joe Biden will nominate Dr. John N. Nkengasong as Ambassador-at-Large and Coordinator of United States Government Activities to Combat HIV/AIDS Globally at the Department of State. The Ambassador-at-Large leads, manages, and oversees the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) – the largest commitment by any nation to address a single disease in history, prevent millions of HIV infections, save lives, and make progress towards ending the HIV/AIDS epidemic. If confirmed,

NAFDAC raises alarm on the use of anti-inflammatory drugs

Late October 2020, Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) said it received a report about the US FDA’s warning on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) around 20 weeks or later in pregnancy which may cause rare but serious kidney problems in an unborn baby. This can result in low amniotic fluid. “After about 20 weeks of pregnancy, the unborn babies’ kidneys produce most of the amniotic fluid, so kidney problems can lead to low